Seiji Niho

7.5k total citations · 2 hit papers
213 papers, 5.1k citations indexed

About

Seiji Niho is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Seiji Niho has authored 213 papers receiving a total of 5.1k indexed citations (citations by other indexed papers that have themselves been cited), including 149 papers in Oncology, 144 papers in Pulmonary and Respiratory Medicine and 40 papers in Epidemiology. Recurrent topics in Seiji Niho's work include Lung Cancer Treatments and Mutations (116 papers), Lung Cancer Research Studies (87 papers) and Lung Cancer Diagnosis and Treatment (62 papers). Seiji Niho is often cited by papers focused on Lung Cancer Treatments and Mutations (116 papers), Lung Cancer Research Studies (87 papers) and Lung Cancer Diagnosis and Treatment (62 papers). Seiji Niho collaborates with scholars based in Japan, United States and South Korea. Seiji Niho's co-authors include Kōichi Goto, Kiyotaka Yoh, Hironobu Ohmatsu, Yutaka Nishiwaki, Shingo Matsumoto, Kaoru Kubota, Shigeki Umemura, Yuichiro Ohe, Kazuhiko Nakagawa and Genichiro Ishii and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Seiji Niho

201 papers receiving 5.0k citations

Hit Papers

Dacomitinib versus gefitinib as first-line treatment for ... 2017 2026 2020 2023 2017 2018 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
    2017 854 citations Yi‐Long Wu, Ying Cheng et al. profile →
  2. Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer and EGFR-Activating Mutations
    2018 331 citations Tony Mok, Ying Cheng et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Seiji Niho Japan 37 3.2k 3.0k 1.1k 894 547 213 5.1k
Kiyotaka Yoh Japan 35 3.0k 0.9× 2.6k 0.9× 1.4k 1.2× 562 0.6× 740 1.4× 271 4.6k
Hiroshi Nokihara Japan 40 3.9k 1.2× 3.3k 1.1× 1.7k 1.5× 656 0.7× 935 1.7× 237 5.9k
Wallace Akerley United States 36 2.7k 0.8× 3.1k 1.1× 1.1k 1.0× 438 0.5× 489 0.9× 156 5.2k
Massimo Barberis Italy 38 1.9k 0.6× 1.5k 0.5× 849 0.8× 727 0.8× 884 1.6× 204 4.2k
Jarushka Naidoo United States 39 5.7k 1.8× 2.6k 0.9× 981 0.9× 853 1.0× 401 0.7× 176 7.2k
Kazumasa Noda Japan 31 4.3k 1.3× 3.7k 1.2× 2.0k 1.8× 1.5k 1.7× 602 1.1× 112 6.3k
Jong‐Mu Sun South Korea 44 4.8k 1.5× 4.4k 1.5× 1.5k 1.3× 486 0.5× 1.0k 1.9× 234 7.1k
Koichi Azuma Japan 42 3.3k 1.0× 3.0k 1.0× 1.5k 1.3× 850 1.0× 949 1.7× 266 6.2k
Nevin Murray Canada 38 3.3k 1.0× 3.3k 1.1× 1.4k 1.3× 1.4k 1.6× 421 0.8× 121 6.2k
Antonio Chella Italy 39 2.9k 0.9× 3.5k 1.2× 1.6k 1.4× 307 0.3× 1.2k 2.2× 130 5.5k

Countries citing papers authored by Seiji Niho

Since Specialization
Citations

This map shows the geographic impact of Seiji Niho's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Seiji Niho with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Seiji Niho more than expected).

Fields of papers citing papers by Seiji Niho

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Seiji Niho. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Seiji Niho. The network helps show where Seiji Niho may publish in the future.

Co-authorship network of co-authors of Seiji Niho

This figure shows the co-authorship network connecting the top 25 collaborators of Seiji Niho. A scholar is included among the top collaborators of Seiji Niho based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Seiji Niho. Seiji Niho is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kanda, Shintaro, Seiji Niho, Takayasu Kurata, et al.. (2025). Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non–Small Cell Lung Cancer Harboring EGFR Mutation. Clinical Cancer Research. 31(12). 2317–2326. 1 indexed citations
2.
Niho, Seiji. (2025). Treatment of small cell lung cancer; advances and future prospects. Respiratory Investigation. 63(4). 680–685.
3.
Tominaga, Keiichi, Yuichi Majima, Makoto Iijima, et al.. (2024). Acute Liver Failure Caused by Isoniazid during Preventive Treatment for Latent Tuberculosis: A Rare Autopsy Case Report. Internal Medicine. 64(14). 2160–2164.
4.
Niho, Seiji, Yasuhiro Gotô, Haruko Daga, et al.. (2024). Phase II study of brigatinib in patients with ROS1 fusion-positive non-small-cell lung cancer: the Barossa study. ESMO Open. 9(8). 103642–103642. 2 indexed citations
5.
Nosaki, Kaname, Yoshitaka Zenke, T. Sasaki, et al.. (2024). JCOG2002: A randomized phase III study of thoracic radiotherapy for extensive stage small cell lung cancer.. Journal of Clinical Oncology. 42(16_suppl). TPS8132–TPS8132. 2 indexed citations
6.
Niho, Seiji, Jun Sato, Miyako Satouchi, et al.. (2024). Long-term follow-up and exploratory analysis of lenvatinib in patients with metastatic or recurrent thymic carcinoma: Results from the multicenter, phase 2 REMORA trial. Lung Cancer. 191. 107557–107557. 6 indexed citations
7.
8.
Shimizu, Yasuo, Naoya Ikeda, Yusuke Nakamura, et al.. (2023). Changes in Peripheral Blood Eosinophil Counts and Risk of Eosinophilic Granulomatosis with Polyangiitis Onset after Initiation of Dupilumab Administration in Adult Patients with Asthma. Journal of Clinical Medicine. 12(17). 5721–5721. 3 indexed citations
9.
Nakamura, Yusuke, et al.. (2023). Transcutaneous gas monitoring is a useful tool to detect respiratory depression during bronchoscopy performed under propofol sedation. Respiratory Investigation. 61(6). 793–799. 1 indexed citations
10.
Kitagawa, Shingo, Yoshitaka Zenke, Kiyotaka Yoh, et al.. (2023). 236TiP Large-scale prospective observational study to develop a liquid-based detection system of minimal residual disease (MRD): LC-SCRUM-MRD. Annals of Oncology. 34. S275–S276. 1 indexed citations
11.
Sawahata, Michiru, Yosikazu Nakamura, Koichi Hagiwara, et al.. (2022). Systemic Adverse Effects Induced by the BNT162b2 Vaccine Are Associated with Higher Antibody Titers from 3 to 6 Months after Vaccination. Vaccines. 10(3). 451–451. 9 indexed citations
12.
Sugimoto, Akira, Shigeki Umemura, Tomohiro Miyoshi, et al.. (2021). High proportion of tumor necrosis predicts poor survival in surgically resected high-grade neuroendocrine carcinoma of the lung. Lung Cancer. 157. 1–8. 3 indexed citations
13.
Sawahata, Michiru, Yosikazu Nakamura, Koichi Hagiwara, et al.. (2021). Age and Smoking Predict Antibody Titres at 3 Months after the Second Dose of the BNT162b2 COVID-19 Vaccine. Vaccines. 9(9). 1042–1042. 52 indexed citations
14.
Sawahata, Michiru, Yosikazu Nakamura, Koichi Hagiwara, et al.. (2021). Attenuation of Antibody Titers from 3 to 6 Months after the Second Dose of the BNT162b2 Vaccine Depends on Sex, with Age and Smoking Risk Factors for Lower Antibody Titers at 6 Months. Vaccines. 9(12). 1500–1500. 25 indexed citations
15.
Nakamura, Masaki, Shun‐Ichiro Kageyama, Hibiki Udagawa, et al.. (2020). Differences in failure patterns according to the EGFR mutation status after proton beam therapy for early stage non-small cell lung cancer. Radiotherapy and Oncology. 149. 14–17. 2 indexed citations
16.
Makinoshima, Hideki, Shigeki Umemura, Ayako Suzuki, et al.. (2018). Metabolic Determinants of Sensitivity to Phosphatidylinositol 3-Kinase Pathway Inhibitor in Small-Cell Lung Carcinoma. Cancer Research. 78(9). 2179–2190. 33 indexed citations
17.
Mok, Tony, Ying Cheng, Xiangdong Zhou, et al.. (2018). Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer and EGFR-Activating Mutations. Journal of Clinical Oncology. 36(22). 2244–2250. 331 indexed citations breakdown →
18.
Miyoshi, Tomohiro, Shigeki Umemura, Yuki Matsumura, et al.. (2016). Genomic Profiling of Large-Cell Neuroendocrine Carcinoma of the Lung. Clinical Cancer Research. 23(3). 757–765. 139 indexed citations
19.
Yoshida, Tatsuya, Genichiro Ishii, Kōichi Goto, et al.. (2014). Podoplanin-Positive Cancer-Associated Fibroblasts in the Tumor Microenvironment Induce Primary Resistance to EGFR-TKIs in Lung Adenocarcinoma with EGFR Mutation. Clinical Cancer Research. 21(3). 642–651. 102 indexed citations
20.
Kubota, Kaoru, Seiji Niho, Sotaro Enatsu, et al.. (2009). Efficacy Differences of Pemetrexed by Histology in Pretreated Patients with Stage IIIB/IV Non-small Cell Lung Cancer: Review of Results from an Open-Label Randomized Phase II Study. Journal of Thoracic Oncology. 4(12). 1530–1536. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kiyotaka Yoh Breakdown of academic impact, for papers by Hiroshi Nokihara Breakdown of academic impact, for papers by Wallace Akerley Breakdown of academic impact, for papers by Massimo Barberis Breakdown of academic impact, for papers by Jarushka Naidoo Breakdown of academic impact, for papers by Kazumasa Noda Breakdown of academic impact, for papers by Jong‐Mu Sun Breakdown of academic impact, for papers by Koichi Azuma Breakdown of academic impact, for papers by Nevin Murray Breakdown of academic impact, for papers by Antonio Chella
Rankless by CCL
2026